AstraZeneca Secures FDA Nod for New Breast Cancer Therapy Etcamah

AstraZeneca secured FDA accelerated approval for Etcamah (camizestrant) combined with CDK4/6 inhibitors to treat HR-positive, HER2-negative advanced breast cancer. The combination reduced disease progression or death risk by 56% compared to standard treatment in the trial supporting the approval.

The FDA simultaneously approved Guardant360 CDx, a companion diagnostic test that identifies patients with ESR1 mutations eligible for the therapy. The dual approval creates a complete treatment pathway for a defined patient subset within the advanced breast cancer market.

Etcamah enters a competitive space dominated by established endocrine therapies and CDK4/6 inhibitors from Pfizer, Eli Lilly, and Novartis. The 56% risk reduction in disease progression or death positions the drug as a differentiated option for patients whose tumors harbor ESR1 mutations, a resistance mechanism that limits current therapies.

AstraZeneca's oncology franchise, already anchored by Enhertu and Tagrisso, gains another pillar in hormone receptor-positive disease. The accelerated pathway requires confirmatory trials, but the magnitude of benefit supports near-term uptake.